Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, ...

The FDA has approved the first anti-PD-L1-based therapies for treatment of certain PD-L1-positive ovarian cancers.

Young adults with IBD are more likely to face step therapy mandates, making clinicians concerned that insurers are ignoring ...

Zuranolone is a novel, rapidly acting, oral medication for the treatment of postpartum depression. Zuranolone is generally ...

Neoadjuvant immunotherapy could considerably improve long-term outcomes and quality of life for patients with desmoplastic ...

Glenn Polyak thought he was out of options when his Stage 4 melanoma spread to his brain, until he became only the second ...

In this episode titled, Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical ...

Three major reviews commissioned by the World Health Organization find that GLP-1 drugs including tirzepatide (sold as Mounjaro and Zepbound), semaglutide (Ozempic and Wegovy), and liraglutide ...

Margaret Krackeler, MD, of Kaiser Permanente Northern California, shares lessons on implementing evidence-based formulary changes for patients with CLL.

Mark Gurarie is a writer covering health topics, technology, music, books, and culture. He also teaches health science and research writing at George Washington University's School of Medical and ...